New Drug Approvals 2012 - Pt. III - Axitinib (INLYTA®)
Tyrosine kinase inhibitors target cancer stem cells in renal cell cancer
Axitinib | C22H18N4OS | CID 6450551 - PubChem
VEGFR inhibitors - Altmeyers Encyclopedia - Department Internal medicine
Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial - ScienceDirect
File:Axitinib.png - Wikipedia
Axitinib | C22H18N4OS | ChemSpider
Product Name : Axitinib N-Glucuronide | Pharmaffiliates
INLYTA® (axitinib) - Cancer Therapy Advisor
Axitinib - wikidoc
AXITINIB
Axitinib - wikidoc
New Drug Approvals 2012 - Pt. III - Axitinib (INLYTA®)
Renal cell carcinoma - Wikiwand
Axitinib-Impurities | Pharmaffiliates
Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade - ScienceDirect
Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial - ScienceDirect
Papillary renal cell carcinoma - Wikipedia
319460-85-0 Axitinib - Watson International Ltd
MedwikiWeb
Phase II Trial Evaluating Axitinib (AG-013736) In Patients With Unresectable, Recurrent Or Metastatic Head And Neck Cancer
New Drug Approvals 2012 - Pt. III - Axitinib (INLYTA®)
Axitinib | C22H18N4OS | CID 6450551 - PubChem
PharmaWiki - Axitinib
Axitinib - wikidoc
Axitinib - wikidoc
Axitinib - Wikipedia
Frontiers | The Paradoxical Role of Cellular Senescence in Cancer
